Logo image of VTVT

VTV THERAPEUTICS INC- CL A (VTVT) Stock Fundamental Analysis

NASDAQ:VTVT - Nasdaq - US9183852048 - Common Stock - Currency: USD

20.2  -0.69 (-3.3%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to VTVT. VTVT was compared to 571 industry peers in the Biotechnology industry. VTVT has a great financial health rating, but its profitability evaluates not so good. VTVT does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

VTVT had negative earnings in the past year.
VTVT had a negative operating cash flow in the past year.
In the past 5 years VTVT always reported negative net income.
In the past 5 years VTVT always reported negative operating cash flow.
VTVT Yearly Net Income VS EBIT VS OCF VS FCFVTVT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -10M -20M -30M -40M -50M

1.2 Ratios

Looking at the Return On Assets, with a value of -42.41%, VTVT is in line with its industry, outperforming 52.93% of the companies in the same industry.
Looking at the Return On Equity, with a value of -121.97%, VTVT is doing worse than 60.04% of the companies in the same industry.
Industry RankSector Rank
ROA -42.41%
ROE -121.97%
ROIC N/A
ROA(3y)-97.48%
ROA(5y)-108.62%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
VTVT Yearly ROA, ROE, ROICVTVT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -1K -2K -3K -4K -5K

1.3 Margins

VTVT does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
VTVT Yearly Profit, Operating, Gross MarginsVTVT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 -5K -10K -15K

More info and screens

7

2. Health

2.1 Basic Checks

VTVT does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, VTVT has less shares outstanding
The number of shares outstanding for VTVT has been reduced compared to 5 years ago.
Compared to 1 year ago, VTVT has a worse debt to assets ratio.
VTVT Yearly Shares OutstandingVTVT Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M
VTVT Yearly Total Debt VS Total AssetsVTVT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M

2.2 Solvency

VTVT has an Altman-Z score of -9.10. This is a bad value and indicates that VTVT is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of VTVT (-9.10) is worse than 71.94% of its industry peers.
There is no outstanding debt for VTVT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -9.1
ROIC/WACCN/A
WACC9.51%
VTVT Yearly LT Debt VS Equity VS FCFVTVT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -50M -100M -150M

2.3 Liquidity

VTVT has a Current Ratio of 6.69. This indicates that VTVT is financially healthy and has no problem in meeting its short term obligations.
VTVT's Current ratio of 6.69 is fine compared to the rest of the industry. VTVT outperforms 65.54% of its industry peers.
A Quick Ratio of 6.69 indicates that VTVT has no problem at all paying its short term obligations.
VTVT's Quick ratio of 6.69 is fine compared to the rest of the industry. VTVT outperforms 65.72% of its industry peers.
Industry RankSector Rank
Current Ratio 6.69
Quick Ratio 6.69
VTVT Yearly Current Assets VS Current LiabilitesVTVT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M

More info and screens

1

3. Growth

3.1 Past

VTVT shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -1537.35%.
The Revenue has grown by 9900.00% in the past year. This is a very strong growth!
EPS 1Y (TTM)-1537.35%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-995.75%
Revenue 1Y (TTM)9900%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to decrease by -139.77% on average over the next years. This is quite bad
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-886.49%
EPS Next 2Y-262.05%
EPS Next 3Y-139.77%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
VTVT Yearly Revenue VS EstimatesVTVT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2M 4M 6M 8M 10M
VTVT Yearly EPS VS EstimatesVTVT Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 -50 -100

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

VTVT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year VTVT is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
VTVT Price Earnings VS Forward Price EarningsVTVT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
VTVT Per share dataVTVT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 -4 -6

4.3 Compensation for Growth

VTVT's earnings are expected to decrease with -139.77% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-262.05%
EPS Next 3Y-139.77%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for VTVT!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

VTV THERAPEUTICS INC- CL A

NASDAQ:VTVT (2/21/2025, 8:00:01 PM)

20.2

-0.69 (-3.3%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-20 2025-02-20/amc
Earnings (Next)05-07 2025-05-07
Inst Owners22.89%
Inst Owner Change-97.85%
Ins Owners1.5%
Ins Owner Change0.05%
Market Cap60.80M
Analysts82.86
Price Target35.7 (76.73%)
Short Float %1.81%
Short Ratio1.64
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)1650%
EPS NQ rev (1m)-987.5%
EPS NQ rev (3m)-987.5%
EPS NY rev (1m)0%
EPS NY rev (3m)-1006.06%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 60.8
P/FCF N/A
P/OCF N/A
P/B 4.05
P/tB 4.05
EV/EBITDA N/A
EPS(TTM)-4.42
EYN/A
EPS(NY)-4.95
Fwd EYN/A
FCF(TTM)-7.77
FCFYN/A
OCF(TTM)-7.77
OCFYN/A
SpS0.33
BVpS4.99
TBVpS4.99
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -42.41%
ROE -121.97%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-97.48%
ROA(5y)-108.62%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.02
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.69
Quick Ratio 6.69
Altman-Z -9.1
F-Score5
WACC9.51%
ROIC/WACCN/A
Cap/Depr(3y)7.41%
Cap/Depr(5y)39.44%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-1537.35%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-995.75%
EPS Next Y-886.49%
EPS Next 2Y-262.05%
EPS Next 3Y-139.77%
EPS Next 5YN/A
Revenue 1Y (TTM)9900%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y11.59%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-50.15%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-50.34%
OCF growth 3YN/A
OCF growth 5YN/A